Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Fund Details
Upturn AI Summary
Invesco Dynamic Pharmaceuticals ETF(PJP)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for PJP
10/28/2026: PJP (2-star) is currently NOT-A-BUY. Pass it for now.
PJP offers targeted exposure to US pharmaceutical companies using a quantitative, dynamic selection strategy that emphasizes earnings momentum and valuation. Its main strength lies in its focused, factor-based approach, which can offer potential outperformance compared to traditional market-cap-weighted alternatives. It is best used as a satellite position to enhance sector exposure rather than a standalone portfolio foundation. Key risks include heavy concentration in a single, highly regulated industry, exposure to patent cliffs, and moderate expense ratios. The fund is most suitable for growth-oriented investors and momentum traders who monitor the regulatory and innovation cycles of the pharmaceutical sector.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Pharmaceutical innovation often drives long-term capital appreciation, aligning well with growth objectives. |
| Momentum investor | Strong fit while signal remains positive | The fund's quantitative rebalancing process naturally emphasizes stocks exhibiting positive price momentum. |
| Value investor | Mixed fit | While pharma stocks can have value characteristics, the focus on dynamic growth metrics may periodically ignore deep-value opportunities. |
| Dividend/Income investor | Mixed fit | While many holdings pay dividends, the fund's objective prioritizes total return and momentum over pure income generation. |
| Low-risk investor | Weak fit | Concentrated exposure to a single industry carries inherent volatility and regulatory risks unsuitable for low-risk portfolios. |
Investor Profile
Ideal Investor Profile
Investors seeking targeted, active exposure to the US pharmaceutical sector who are comfortable with industry-specific risk and volatility.
Suitability
Best suited for long-term investors or tactical traders looking to overweight the pharmaceutical industry within a diversified healthcare strategy.
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Volatility | Medium / high | Single-sector concentration leads to higher price swings compared to diversified market indices. |
| Market risk | Medium / high | The fund is highly sensitive to overall healthcare sector sentiment and macroeconomic interest rate shifts. |
| Concentration | High | Limiting the portfolio to the pharmaceutical industry increases risk if that specific sector faces regulatory or patent challenges. |
| Tracking/expense | Low | The management fee is moderate, and tracking error is generally well-controlled by the issuer. |
| Liquidity | Medium | While major holdings are liquid, smaller pharmaceutical stocks in the index can occasionally experience wider spreads during market stress. |
| Business/sector quality | Medium / high | Business success is heavily dependent on the high-risk, high-reward nature of R&D and pharmaceutical litigation. |
Risk Analysis
Volatility
PJP displays higher historical volatility than broad market indices like the S&P 500, characteristic of sector-specific and pharmaceutical-focused funds.
Market Risk
The fund is inherently exposed to legislative, regulatory, and patent-related risks, which are unique and significant factors affecting the pharmaceutical industry.
What the ETF Owns
| Exposure Type | Exposure | Weight (%) | Retail Investor Read |
|---|---|---|---|
| Sector | US Pharmaceutical Equities | 98.5 | This represents the core equity holdings that provide direct exposure to the US pharmaceutical industry. |
| Cash/collateral | Cash and Cash Equivalents | 1.5 | Small cash buffers are held for liquidity purposes and to facilitate rebalancing activities. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Very Smooth
The stock has followed a highly orderly price path with minimal short-term disruption.
Analysis of Past Performance
Type ETF | Historic Profit 55.1% | Avg. Invested days 102 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  5.0 | ETF Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/28/2026 |
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.